Patient-Specific Dosimetry Calculations Using Mathematic Models of Different Anatomic Sizes During Therapy with 111In-DTPA-d-Phe1-Octreotide Infusions After Catheterization of the Hepatic Artery

Journal of Nuclear Medicine

Dimitrios K. Kontogeorgakos¹  Georgios S. Limouris¹  Panagiotis A. Dimitriou¹  Lambros J. Vlahos¹ 

[1] Nuclear Medicine Division, Radiology Department, Aretaieion University Hospital, Athens, Greece Nuclear Medicine Division, Radiology Department, Aretaieion University Hospital, Athens, Greece Nuclear Medicine Division, Radiology Department, Aretaieion University Hospital, Athens, Greece

关键词: neuroendocrine tumors;    dosimetry;    ¹¹¹In-DTPA-d-Phe¹-octreotide;    peptide therapy;    hepatic artery catheterization;   

DOI  :  

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

The aim of the study was to provide dosimetric data on intrahepatic 111In-diethylenetriaminepentaacetic acid (DTPA)-d-Phe1-octreotide therapy for neuroendocrine tumors with overexpression of somatostatin receptors. Methods: A dosimetric protocol was designed to estimate the absorbed dose to the tumor and healthy tissue in a course of 48 treatments for 12 patients, who received a mean activity of 5.4 ± 1.7 GBq per session. The patient-specific dosimetry calculations, based on quantitative biplanar whole-body scintigrams, were performed using a Monte Carlo simulation program for 3 male and 3 female mathematic models of different anatomic sizes. Thirty minutes and 2, 6, 24, and 48 h after the radionuclide infusion, blood-sample data were collected for estimation of the red marrow radiation burden. Results: The mean absorbed doses per administered activity (mGy/MBq) by the critical organs liver, spleen, kidneys, bladder wall, and bone marrow were 0.14 ± 0.04, 1.4 ± 0.6, 0.41 ± 0.08, 0.094 ± 0.013, and (3.5 ± 0.8) × 10−3, respectively; the tumor absorbed dose ranged from 2.2 to 19.6 mGy/MBq, strongly depending on the lesion size and tissue type. Conclusion: The results of the present study quantitatively confirm the therapeutic efficacy of transhepatic administration; the tumor–to–healthy-tissue uptake ratio was enhanced, compared with the results after antecubital infusions. Planning of treatment was also optimized by use of the patient-specific dosimetric protocol.

【 授权许可】

Unknown